CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics Holdings, Inc., trading under the ticker PBAX on Nasdaq, is the combined entity that resulted from Phoenix Biotech Acquisition Corp's de-SPAC transaction with clinical-stage biopharmaceutical company Cero Therapeutics. Phoenix Biotech Acquisition Corp, sponsored by Phoenix Biotech Sponsor LLC, completed its IPO in 2021 with a focus on the life sciences and biotechnology sector. Cero Therapeutics develops engineered chimeric endogenous receptor T cell therapies, known as CER-T, targeting hematologic malignancies and solid tumors. The company filed an 8-K current report with the SEC on May 29, 2025, as part of its routine public disclosure obligations. Sign up for full data and filing history on SpacDesk.